Senti Biosciences Reports $14.7 Million Net Loss in Q2 2025, Seeks Additional Funding

Senti Biosciences, Inc. reported a net loss of $14.7 million for the second quarter of 2025, compared to a loss of $11.2 million in the same period of 2024. For the first half of 2025, the company’s net loss totaled $28.8 million, up from $23.3 million in the prior year. The increase in losses is attributed primarily to higher operating expenses, which rose to $16.8 million in Q2 2025 from $13.4 million in Q2 2024, driven by increased research and development costs and general administrative expenses. The company’s accumulated deficit reached $326.0 million as of June 30, 2025, compared to $297.1 million at the end of 2024.

Senti's total operating expenses for the first half of 2025 were $33.2 million, up from $29.7 million in the same period last year. Research and development expenses increased to $19.3 million from $17.9 million, reflecting a rise in external services and supplies costs. General and administrative expenses also grew, reaching $13.9 million compared to $11.7 million in the prior year, largely due to increased personnel-related costs. The company reported cash and cash equivalents of $21.6 million as of June 30, 2025, down from $48.3 million at the end of 2024.

In terms of strategic developments, Senti Biosciences has made significant organizational changes, including the conversion of 21,157 shares of Series A redeemable convertible preferred stock into 21,157,000 shares of common stock in March 2025. This conversion followed stockholder approval and was part of a broader effort to strengthen the company's equity position. Additionally, the company entered into a 2025 ATM Agreement with Leerink Partners, allowing it to raise up to $17.5 million through the sale of common stock, although it reported only $0.6 million in net proceeds from this agreement in the first half of 2025.

Operationally, Senti has continued to advance its clinical programs, including the SENTI-202 trial for blood cancers, which received Orphan Drug Designation from the FDA. However, the company has faced challenges, such as the cessation of patient enrollment in the SN301A trial due to observed dose-limiting toxicities. As of June 30, 2025, Senti's employee headcount had increased, reflecting its ongoing efforts to expand its operational capabilities in research and development.

Looking ahead, Senti Biosciences anticipates continued significant operating losses as it progresses with its clinical trials and research initiatives. The company has indicated that it will require additional funding to maintain operations and support its development strategy, emphasizing the need for successful capital raising efforts to ensure its long-term viability. The management remains focused on advancing its gene circuit platform technologies and expanding its product pipeline, although substantial doubt exists regarding its ability to continue as a going concern without securing further financing.